The new year promises rapid innovation to stay ahead of the curve, but 2025 also reveals a shifting landscape that will likely result in significant headwinds for the life sciences sector. From rapid advancements in technology and strict regulatory environments to shifting healthcare models, Savills explores eight factors life sciences companies should prepare for as they navigate the ever-evolving market ahead.
1. Increased market competition
An onslaught of high-profile (and high-revenue) drugs will face patent expiration dates this year, which will heighten competition from generics and biosimilars. Companies will feel pressured by pricing, market share and patient access, and will look to stay ahead of the curve through rapid innovation, producing vaccines and specialty medicines that diversify their portfolios.
2. Regulatory and legal challenges
Strict global regulatory environments are increasingly focused on drug pricing, transparency and patient safety. New and ongoing legal challenges surrounding patent infringements, product liabilities and regulatory non-compliance pose risks to financial stability and reputation. In the United States, there is uncertainty about how this may shift under the new administration, but in the meantime, adapting to the changes will require significant resources.
3. Global economic conditions
If the prospect of a global economic slowdown becomes a reality, it could reduce healthcare spending on both supply and demand sides, amplifying existing challenges within the sector itself as well as impacting the growth potential of companies. As recent recessions in 2008 and 2020 proved, the myth of “recession-proof” healthcare has been debunked.
4. Rising research and development costs
Costs are on the rise in research and development, as companies encounter challenges including increased complexity in research methods and technologies, higher skilled labor costs, stricter regulatory processes and capital-intensive research equipment and facilities. Pressured to innovate, maintain market competitiveness and achieve commercial success, companies must employ strategies to improve their R&D productivity to offset these steady cost increases.
5. Pricing pressure
Public and political scrutiny over drug pricing and transparency is intensifying, particularly in the United States. Coupled with changes in healthcare insurance and reimbursement rates, this can pressure margins and affect profitability. The companies that are more thoughtful in considering their balance sheet will be more successful at maintaining a better financial position.
6. Technological advancements
The rapid advancements of artificial intelligence (AI), machine learning, biotech and personalized medicine are helping accelerate drug development. Ongoing investment in new technologies and methodologies—and the skilled workers needed to leverage them—will be critical to stay relevant and efficient in research and operations. Companies like Moderna, for example, are employing this tactic by increasing their staff significantly, with 70% of its open positions being tech related.
7. Supply chain vulnerabilities
The global supply chain remains vulnerable to disruptions. When exacerbated by geopolitical tensions or health pandemics, it can affect the production and distribution of medications. New tariffs will impact how drugs are manufactured and come to market in North America, as they influence the import of raw goods and export of products. This factor prompts a growing need for sustainable practices across manufacturing and distribution processes, but it will require significant adaptation and investment.
8. Changes in healthcare systems
Today’s healthcare system is more patient-focused and is moving to a proactive model of care and treatment. This evolution will give patients more value-based care centered on prevention, access and coordination versus traditional treatment-focused interventions. In light of this shift, companies may be required to modify their overall strategy.
With 2025 in full swing, life sciences companies face a rapidly evolving landscape filled with both opportunities and significant challenges. Success will depend on strategic adaptation, investment in emerging technologies and a proactive approach to supply chain resilience and healthcare system changes. By anticipating and addressing these factors, companies can position themselves for long-term sustainability in an increasingly complex environment.
Written by: Austin Barrett | Vice Chairman, Head of Life Sciences | Savills | + 1650 269 9941